" class="no-js "lang="en-US"> Treadwell Therapeutics - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Treadwell Therapeutics | Pharmtech Focus

Treadwell Therapeutics

About Treadwell Therapeutics

Treadwell Therapeutics

Related Story

Appointments

 Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer | MTA

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

February 3 2023

Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first-in-class therapeutics for highly aggressive cancers, […]

Diseases

 Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia | Pharmtech Focus

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia

April 27 2022

Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced […]